



**APPENDIX 4C – 1ST QUARTER FY19/20 QUARTERLY REPORT**

Resonance Health Limited (ASX: RHT) (“Resonance Health” or “Company”) today releases its Appendix 4C – Quarterly Report for the period ended 30 September 2019.

**Summary of Key Financials and Business Performance**

- Cash receipts from customers for the September 2019 quarter were \$891K, an increase of 31% versus the September quarter in the previous year.
- Total revenue for the September quarter was \$956K (unaudited), an increase of 8% versus the June quarter and an increase of 12% versus the September quarter in the previous year.
- Cash on hand as of 30 September 2019 was \$3.25m, an increase of \$171K over the June 2019 quarter.
- The Company signed a new contract to provide products and services to a pharmaceutical company for their clinical trial (19 July 2019 “Resonance Health contracted for new clinical trial”).
- The Company executed several non-material amendments and extensions to existing contracts with pharma, the total aggregate sum of these is USD \$373,950, subject to full completion of these trials.
- Service provision to pharma for their clinical trials is well under way for all trials.
- Progress has been made in all R&D projects. Consistent with the Company’s growth aspirations Resonance Health is strongly committed to several R&D streams: Investment in R&D has continued but with a greater focus on nearer-term commercial outcomes and diversification of the R&D pipeline. In addition to imaging projects, the Company is expanding its AI ambitions, and is also investing in a small number of molecular projects.



+Rule 4.7B

## Appendix 4C

### Quarterly report for entities subject to Listing Rule 4.7B

Introduced 31/03/00 Amended 30/09/01, 24/10/05, 17/12/10, 01/09/16

**Name of entity**

Resonance Health Limited	
<b>ABN</b>	<b>Quarter ended (“current quarter”)</b>
96 006 762 492	30 September 2019

<b>Consolidated statement of cash flows</b>	<b>Current quarter \$A’000</b>	<b>Year to date (3months) \$A’000</b>
<b>1. Cash flows from operating activities</b>		
1.1 Receipts from customers	891	891
1.2 Payments for		
(a) research and development	(118)	(118)
(b) product manufacturing and operating costs		
(c) advertising and marketing	(51)	(51)
(d) leased assets		
(e) staff costs	(440)	(440)
(f) administration and corporate costs	(154)	(154)
1.3 Dividends received (see note 3)		
1.4 Interest received	27	27
1.5 Interest and other costs of finance paid		
1.6 Income taxes paid		
1.7 Government grants and tax incentives		
<b>1.9 Net cash from / (used in) operating activities</b>	<b>155</b>	<b>155</b>

+ See chapter 19 for defined terms.

<b>Consolidated statement of cash flows</b>	<b>Current quarter \$A'000</b>	<b>Year to date (3months) \$A'000</b>
<b>2. Cash flows from investing activities</b>		
2.1 Payments to acquire:		
(a) property, plant and equipment	(0)	(0)
(b) businesses (see item 10)		
(c) investments		
(d) intellectual property		
(e) other non-current assets		
2.2 Proceeds from disposal of:		
(a) property, plant and equipment		
(b) businesses (see item 10)		
(c) investments		
(d) intellectual property		
(e) other non-current assets		
2.3 Cash flows from loans to other entities		
2.4 Dividends received (see note 3)		
<b>2.6 Net cash from / (used in) investing activities</b>	<b>(0)</b>	<b>(0)</b>

<b>3. Cash flows from financing activities</b>		
3.1 Proceeds from issues of shares		
3.2 Proceeds from issue of convertible notes		
3.3 Proceeds from exercise of share options		
3.4 Transaction costs related to issues of shares, convertible notes or options		
3.5 Proceeds from borrowings		
3.6 Repayment of borrowings		
3.7 Transaction costs related to loans and borrowings		

+ See chapter 19 for defined terms.

<b>Consolidated statement of cash flows</b>	<b>Current quarter \$A'000</b>	<b>Year to date (3months) \$A'000</b>
3.8 Dividends paid		
3.9 Other (provide details if material)		
<b>3.10 Net cash from / (used in) financing activities</b>		

<b>4. Net increase / (decrease) in cash and cash equivalents for the period</b>		
4.1 Cash and cash equivalents at beginning of quarter/year to date	3081	3081
4.2 Net cash from / (used in) operating activities (item 1.9 above)	155	155
4.3 Net cash from / (used in) investing activities (item 2.6 above)	(0)	(0)
4.4 Net cash from / (used in) financing activities (item 3.10 above)	(0)	(0)
4.5 Effect of movement in exchange rates on cash held	16	16
<b>4.6 Cash and cash equivalents at end of quarter</b>	<b>3252</b>	<b>3252</b>

<b>5. Reconciliation of cash and cash equivalents</b> at the end of the quarter (as shown in the consolidated statement of cash flows) to the related items in the accounts	<b>Current quarter</b> <b>\$A'000</b>	<b>Previous quarter</b> <b>\$A'000</b>
5.1 Bank balances	3252	3081
5.2 Call deposits		
5.3 Bank overdrafts		
5.4 Other (provide details)		
<b>5.5 Cash and cash equivalents at end of quarter (should equal item 4.6 above)</b>	<b>3252</b>	<b>3081</b>

**6. Payments to directors of the entity and their associates**

- 6.1 Aggregate amount of payments to these parties included in item 1.2
- 6.2 Aggregate amount of cash flow from loans to these parties included in item 2.3
- 6.3 Include below any explanation necessary to understand the transactions included in items 6.1 and 6.2

**Current quarter**  
**\$A'000**

60

\$45K – Directors fees  
\$15K – Consultancy fees

<b>7.</b>	<b>Payments to related entities of the entity and their associates</b>	<b>Current quarter \$A'000</b>
7.1	Aggregate amount of payments to these parties included in item 1.2	
7.2	Aggregate amount of cash flow from loans to these parties included in item 2.3	
7.3	Include below any explanation necessary to understand the transactions included in items 7.1 and 7.2	

<b>8.</b>	<b>Financing facilities available</b> <i>Add notes as necessary for an understanding of the position</i>	<b>Total facility amount at quarter end \$A'000</b>	<b>Amount drawn at quarter end \$A'000</b>
8.1	Loan facilities		
8.2	Credit standby arrangements		
8.3	Other (please specify)		
8.4	Include below a description of each facility above, including the lender, interest rate and whether it is secured or unsecured. If any additional facilities have been entered into or are proposed to be entered into after quarter end, include details of those facilities as well.		

+ See chapter 19 for defined terms.

<b>9.</b>	<b>Estimated cash outflows for next quarter</b>	<b>\$A'000</b>
9.1	Research and development	(149)
9.2	Product manufacturing and operating costs	-
9.3	Advertising and marketing	(59)
9.4	Leased assets	-
9.5	Staff costs	(395)
9.6	Administration and corporate costs	(97)
	<b>Estimated cash outflows</b>	<b>(700)</b>
9.7	Estimated receivables	820
<b>9.8</b>	<b>Total estimated cash inflows</b>	<b>120</b>

<b>10.</b>	<b>Acquisitions and disposals of business entities (items 2.1(b) and 2.2(b) above)</b>	<b>Acquisitions</b>	<b>Disposals</b>
10.1	Name of entity		
10.2	Place of incorporation or registration		
10.3	Consideration for acquisition or disposal		
10.4	Total net assets		
10.5	Nature of business		

## Compliance statement

- 1 This statement has been prepared in accordance with accounting standards and policies which comply with Listing Rule 19.11A.
- 2 This statement gives a true and fair view of the matters disclosed.

Sign here: **Agha Shahzad Pervez**  
(Company secretary)

Date: 28 October 2019

## Notes

1. The quarterly report provides a basis for informing the market how the entity's activities have been financed for the past quarter and the effect on its cash position. An entity that wishes to disclose additional information is encouraged to do so, in a note or notes included in or attached to this report.
2. If this quarterly report has been prepared in accordance with Australian Accounting Standards, the definitions in, and provisions of, *AASB 107: Statement of Cash Flows*

+ See chapter 19 for defined terms.

apply to this report. If this quarterly report has been prepared in accordance with other accounting standards agreed by ASX pursuant to Listing Rule 19.11A, the corresponding equivalent standard applies to this report.

3. Dividends received may be classified either as cash flows from operating activities or cash flows from investing activities, depending on the accounting policy of the entity.